Navigation Links
Neuralstem's ALS Trial on Clinical Hold
Date:2/20/2009

l the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS).

In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended September 30, 2008.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... DALLAS , July 3, 2015 ... report "Cardiac Monitoring & Cardiac Rhythm Management Market ... Output Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber ... published by MarketsandMarkets, the global Cardiac Monitoring (CM) ... poised to reach $26,646.5 Million by 2020 from ...
(Date:7/3/2015)... , July 3, 2015 Redwood ... Broda Technologies Co., Ltd., operating in both the US ... company,s proprietary IntelliGel ® supramolecular hydrogel technology in ... and other ophthalmic therapies. The Broda technology offers many ... is a free-forming liquid and with low concentrations of ...
(Date:7/2/2015)... , July 2, 2015 ResMed Inc. (NYSE: ... fourth quarter and fiscal year ended June 30, 2015 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2
... SAN FRANCISCO , April 21, 2010 ... announced an agreement,with 100X Imaging, Inc. (100X Imaging) to develop and ... exclusive,rights to develop and market products based on this image indexing ... ...
... March 23 The innovative therapies for lung failure from medical device company Novalung GmbH continue to gain acceptance.  Additional financing will allow the Talheim ( Germany ) based ... ... ... ...
Cached Medicine Technology:Strand to Develop and Market Breakthrough Software Solutions to Manage Insights Associated With Microscopy Images 2Novalung Records 50% Growth 2Novalung Records 50% Growth 3
(Date:7/4/2015)... ... ... Chronic Neck Pain. Neck pain is no small problem. NIH ... Another 19% suffer from head, migraine, or facial pain, in some cases related to ... workers must deal with neck pain. Strategies for mitigating neck pain range ...
(Date:7/3/2015)... ... ... Bank will hopefully be getting a large donation of canned food items at the ... are making it their mission to collect as many canned items as possible. Donations do ... public as well. As part of the canned food drive, these local chiropractors will be ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... speaker lineup for its 2015 Annual Conference , the premiere continuing ... at the Renaissance Orlando at SeaWorld in Orlando, Florida. Speakers include the ...
(Date:7/3/2015)... LENEXA, Kan. (PRWEB) , ... July 03, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Smoothies are ... is a good blender and easily accessible, quality ingredients. Aurora Natural is proud to ... for an added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is ...
Breaking Medicine News(10 mins):Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2
... have been known to cause momentary periods of blindness. ... how much information people can hold in their visual short-term ... miss visual images that pass right before our eyes when ... is not all. The new research indicates that we can ...
... the body from tissue damage also increases the risk ... University School of Medicine in St. Louis tested the ... survive the effects of toxic chemotherapeutic agents. ,They ... tumours in mice exposed to a carcinogen, reports the ...
... a deficient gene that is also responsible for the ... causes congenital blindness in children. The researchers’ study regarding ... is published in the August issue of the journal ... is lacking in these patients, by gene therapy should ...
... Kerala has claimed to have found a rat's tail in a ... 13, 2005) a soft drink from the Coca Cola Company.,There has ... to file a petition against // the company under the Prevention ... respond to the allegation. The allegation against Coke comes at a ...
... A new technique known as the Checkerboard Tissue Microarray ... of prostate cancer. ,Needle biopsies, blood ... determine how aggressive the cancer // is and whether ... tests are however not very accurate, resulting in thousands ...
... Johns Hopkins University School of Medicine had said in a ... of Medicine that the disease called Rocky Mountain spotted fever ... an outbreak. ,The research highlights the importance of the ... that could be traced back to ticks carried into to ...
Cached Medicine News:Health News:Enzyme Responsible For Congenital Blindness 2Health News:New advance in prostate cancer management 2Health News:Spread Of Rocky Mountain Spotted Fever Is A Probability, Say Experts 2
Swedish Knee Cage -- hinged to track knee motion. Effective control of genu recurvatum (back knee or knee hyperextension). Fits left or right....
... Infrapatellar Band uses an aircell ... patellar tendon helping to relieve ... patella tendonitis. Focusing the pressure ... tubercle with less constriction of ...
Designed to provide continuous cold therapy to the shoulder and back. Helps to reduce pain and swelling and speed rehab....
... fusion, dislocation, reconstruction or soft tissue ... to be positioned in external, neutral ... injury this orthosis can be used ... healing process and can position the ...
Medicine Products: